Allterum Therapeutics

What Allterum Therapeutics does

Allterum Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 as a spin-out from Fannin, Houston's early-stage life sciences development group. The company is headquartered at 3900 Essex Lane, Suite 575, Houston, Texas, and operates with a small named leadership team of approximately 13 across executive, clinical operations, R&D, finance, and technical operations functions. Allterum is developing 4A10, a first-in-class monoclonal antibody targeting CD127 (also known as IL-7Rα), for the treatment of CD127-expressing cancers. The 4A10 antibody was invented by Dr. Scott Durum's group at the National Cancer Institute (NCI) and is exclusively licensed to Fannin/Allterum. The company is initially focused on relapsed/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and B-cell hematologic malignancies — a population of roughly 160 new cases of relapsed/refractory T-cell ALL per year with poor prognosis and limited treatment options — and is expanding preclinically into CD127-overexpressing lymphomas and solid tumors (an addressable pool of ~80,000 metastatic cases per year).

Allterum's underlying technology leverages the patient's own immune system to target cancer cells expressing CD127, a receptor complex on T-cells and pre-B-cells that plays a critical role in leukemia oncogenesis, chemotherapy resistance, and steroid resistance. The asset has been granted FDA Orphan Drug Designation and Rare Pediatric Disease Designation (October 2020), IND clearance (October 2025), and Fast Track Designation (November 2025). Manufacturing is conducted via cGMP partnerships with FUJIFILM Diosynth Biotechnologies (College Station, TX) and GBI Biomanufacturing (strategic collaboration announced October 2024). Phase I clinical trial sites are at Texas Children's Hospital / Baylor College of Medicine (Chair: Dr. Eric Schafer), Children's Hospital of Philadelphia (Vice-Chair: Dr. Susan Rheingold), and The University of Texas MD Anderson Cancer Center (Dr. Elias Jabbour). Preclinical data have been published in peer-reviewed journals including Leukemia, Blood, Nature Communications, and JCI.

Allterum is a pre-revenue company with no commercial product sales and no disclosed pricing. The therapy is available only through clinical trial participation under the company's Expanded Access Policy. Funding has been sourced primarily from non-dilutive grants — over $15.9 million from the Cancer Prevention and Research Institute of Texas (CPRIT) across multiple awards and approximately $3 million in NIH/NCI SBIR grants — supplemented by an undisclosed Series Seed round led by Fannin Innovation Studio in December 2020. The company has no subsidiaries, no acquisitions, and operates only in U.S. clinical trial sites. Its GTM is an enterprise field-sales / clinical-trial-enrollment motion executed through KOLs at elite academic medical centers rather than any commercial sales channel. Revenue mechanics upon potential approval would be one-time license / biologic product sales, though no such commercialization infrastructure is currently in place.

Name

Allterum Therapeutics

Legal name

Allterum Therapeutics, Inc.

Website

https://allterum.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Allterum Therapeutics is a Houston-based clinical-stage biopharmaceutical company developing 4A10, a first-in-class anti-CD127 monoclonal antibody, for relapsed/refractory T-cell ALL and other CD127-expressing hematologic and solid tumor malignancies.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

Keywords

• Monoclonal antibody therapy
• Cancer immunotherapy
• Leukemia therapeutics
• Biopharmaceutical development
• Oncology biologics

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Clinical-stage biopharmaceutical (pre-revenue): Allterum Therapeutics is a pre-revenue clinical-stage biopharmaceutical company. The company is developing 4A10, an anti-CD127 monoclonal antibody, through clinical trials. Revenue generation is not yet applicable; the company is funded by grants and equity financing. Once a therapy is approved, revenue would be generated through product sales as a licensed biologic.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Allterum Therapeutics develops 4A10, an investigational anti-CD127 (IL-7Rα) monoclonal antibody therapeutic for the treatment of CD127-expressing cancers. The asset is initially targeted at patients with relapsed/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and B-cell hematologic malignancies, with planned expansion into CD127-overexpressing lymphomas and solid tumors. The product is currently available only through participation in Phase I clinical trials at major U.S. academic cancer centers.

Product overview

Allterum Therapeutics is a biopharmaceutical company developing 4A10, a monoclonal antibody therapeutic targeting the CD127 (IL-7Rα) pathway. The company is initially focused on hematologic malignancies, particularly relapsed/refractory T-cell Acute Lymphoblastic Leukemia and B-cell malignancies, with plans to expand into lymphomas and solid tumors with CD127 over-expression. The 4A10 antibody was developed at the National Cancer Institute and represents the first immunotherapy approach to target CD127.

Differentiator

Problem solved

Functional benefit

Products and services

• 4A10 4A10 is an investigational anti-CD127 (IL-7Rα) monoclonal antibody therapeutic developed for treating relapsed/refractory hematologic malignancies, including T-cell Acute Lymphoblastic Leukemia (T-ALL), B-cell malignancies, and lymphomas with CD127 over-expression. The antibody leverages the patient's immune system to target cancer cells for destruction and is currently available only through participation in Phase I clinical trials at major U.S. academic cancer centers.

Quantifiable outcome

• Over 90% five-year survival rate for children with ALL with standard frontline chemotherapy, but outcomes are poor for relapsed/refractory patients — creating a critical unmet need that Allterum addresses
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered core.

• GBI BiomanufacturingcoreStrategic or Co-development Partner · 7 October 2024GBI Biomanufacturing and Allterum entered into a strategic collaboration to manufacture the therapeutic antibody for clinical trials. This collaboration was announced in October 2024 to support the production of 4A10 for Phase I clinical development.
• FUJIFILM Diosynth BiotechnologiescoreStrategic or Co-development Partner · 21 April 2020FUJIFILM Diosynth Biotechnologies is Allterum's manufacturing partner and is completing cGMP scale-up and manufacturing of the 4A10 drug in advance of the Phase I clinical trial. This partnership enables the production of clinical-grade biologic material for human trials.
• National Cancer Institute (NCI)coreStrategic or Co-development PartnerDr. Scott Durum and his group at the National Cancer Institute invented the 4A10 antibody technology. NCI continues to actively collaborate on developing the program. NCI is the federal government's principal agency for cancer research and training, part of the NIH.
• Texas Children's Hospital / Baylor College of MedicinecoreStrategic or Co-development PartnerDr. Eric Schafer, Assistant Professor in Pediatrics-Oncology at Texas Children's Hospital and Baylor College of Medicine, serves as Chair of Allterum's Phase I clinical trial. TCH/BCM is one of the premier pediatric hospitals in the nation (tied for 3rd overall Best Children's Hospital, #3 for pediatric cancer per U.S. News & World Report 2019).
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development PartnerDr. Susan Rheingold, Medical Director of the Oncology Outpatient Clinic at CHOP, serves as Vice-Chair of Allterum's Phase I clinical trial. Sarah Tasian, MD, Chief of the Hematologic Malignancies Program at CHOP, is collaborating with Allterum to evaluate 4A10 in PDX models of B-ALL.
• The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development PartnerDr. Elias Jabbour, Professor of Medicine in the Department of Leukemia at MD Anderson, serves as a collaborator in the Phase I clinical trial. Dr. Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology, collaborates on expansion into other IL-7R expressing cancers.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Amgen: Large-cap biopharmaceutical company with established hematologic oncology franchise including Blincyto (blinatumomab) for B-cell ALL. Comparable as a major oncology biologic developer operating in the same leukemia treatment landscape that Allterum targets with 4A10.
• Novartis: Global biopharmaceutical company that markets Kymriah, the first FDA-approved CAR-T therapy for pediatric B-cell ALL. Direct overlap with Allterum's relapsed/refractory ALL patient population, though with a different modality (CAR-T vs monoclonal antibody).
• Gilead Sciences (Kite): Owns Kite Pharma, whose Tecartus is approved for relapsed/refractory B-cell ALL and mantle cell lymphoma. Competitor in the r/r ALL space via CAR-T cell therapy, overlapping with Allterum's relapsed/refractory T-cell ALL focus.
• Seagen: Major oncology biotech specializing in antibody-based therapies including ADCs (Adcetris for lymphoma). Broader portfolio company with relevant hematologic oncology commercial infrastructure and antibody-drug development expertise.

Direct peers

• Jazz Pharmaceuticals: Specialty biopharmaceutical company with deep hematologic/oncology franchise including Erwinaze (asparaginase for ALL) and Vyxeos for AML. Comparable commercial-stage player in rare hematologic malignancies with similar regulatory strategy (orphan indications).
• Servier Pharmaceuticals: Markets Oncaspar (pegaspargase), a cornerstone ALL therapy, and acquired Shire's oncology portfolio including the IDHIFA and TIBSOVO programs. Operates a dedicated U.S. rare oncology business unit with similar orphan-drug commercial model applicable to Allterum's relapsed/refractory ALL focus.
• ADC Therapeutics: Late-stage clinical biotechnology company developing antibody-drug conjugates for hematologic malignancies including Zynlonta (loncastuximab tesirine) for DLBCL. Similar stage and therapeutic area focus to Allterum, with comparable strategy of targeting CD127-overlapping pathways in lymphoma.
• MacroGenics: Clinical-stage biopharmaceutical company developing monoclonal antibodies for cancer, with approved product Margenza (margetuximab) and pipeline targeting hematologic malignancies. Closely analogous business model — clinical-stage mAb oncology biotech pursuing orphan indications.

Emerging players

• Genmab: Biotechnology company specializing in antibody therapeutics for cancer, with approved products including Darzalex (with J&J) and multiple pipeline candidates in hematologic malignancies. Comparable antibody-platform focus and clinical-stage oncology pipeline.
• Innate Pharma: Clinical-stage immuno-oncology company developing antibody-based therapeutics targeting innate immune cells. Similar stage of development and biologic-immunotherapy approach to oncology, with comparable need to validate novel mechanism-of-action in hematologic indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/allterum-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allterum Therapeutics